Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
NPC Blog
NPC Blog
2008 Archives
2007 Archives
2006 Archives
Search Archives
Archives
  • October 2008 (1)
  • September 2008 (1)
  • August 2008 (2)
  • July 2008 (2)
  • June 2008 (4)
  • May 2008 (1)
  • April 2008 (1)
  • March 2008 (4)
  • February 2008 (1)
  • April 2007 (1)
  • December 2006 (1)
  • October 2006 (1)
  • September 2006 (1)
  • July 2006 (2)
  • June 2006 (3)
  • Blog Updates
    Signup here and receive blog posts directly in your inbox.

     

    Subscribe in a reader

     
    E-Alerts
    Signup to receive news and announcements from Nutra Pharma
    Name:
    Email:

    Yes, in addition to e-alerts, please sign me up to receive Nutra Pharma Blog postings via email.

     
    Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

    NPC Blog

    A Fascinating Look into the Science of Nature

    Throughout history, civilizations may rise and fall, but one thing remains constant — nature finds a way to adapt and survive.

    How does this happen and what can we hope to learn from it? These are precisely the questions that we are asking ourselves at Nutra Pharma.

    As many of you know, our drug discovery holding ReceptoPharm is developing treatments for Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Herpes, and the Human Immunodeficiency Virus (HIV) using modified cobra venom and cobratoxin.

    Studying one of the deadliest creatures on the Planet for treating some of the worlds’ most devastating diseases may seem odd to many of you. It is, but what we have realized is that cobras may in fact hold the key to the success of our drug development for treating neurological and autoimmune disorders.

    If you still are not convinced this is possible, just consider these odd sources for leading drugs:

    • Prialt (Elan) – Venom from the Conus snail used to treat pain
    • Aggrastat (Merck) – Venom from the African Saw-Scaled Viper used to prevent blood clots
    • Exenatide (Eli Lilly and Amylin) — Poisonous Saliva from the Gila Monster used to treat diabetes

    For your viewing pleasure, here is a short presentation from famed oceanic explorer, David Gallo, showing us how nature has equipped itself to adapt and survive, even in the harshest of conditions. Maybe those of us in the life science and biotechnology industries can learn something from these amazing sea creatures:

    (For those reading this in your email, click here to see the video)


    del.icio.us:A Fascinating Look into the Science of Nature digg:A Fascinating Look into the Science of Nature spurl:A Fascinating Look into the Science of Nature wists:A Fascinating Look into the Science of Nature simpy:A Fascinating Look into the Science of Nature newsvine:A Fascinating Look into the Science of Nature blinklist:A Fascinating Look into the Science of Nature furl:A Fascinating Look into the Science of Nature reddit:A Fascinating Look into the Science of Nature fark:A Fascinating Look into the Science of Nature blogmarks:A Fascinating Look into the Science of Nature Y!:A Fascinating Look into the Science of Nature smarking:A Fascinating Look into the Science of Nature magnolia:A Fascinating Look into the Science of Nature segnalo:A Fascinating Look into the Science of Nature gifttagging:A Fascinating Look into the Science of Nature


    1 Comment

      I’ve just followed a link from Feedburner, just like to commend you guys on using a blog to communicate ideas, and new ways of thinking about pharmaceuticals and the industry etc.

      Its interesting to see someone in your sector jumping onto the web. I found the video super by the way.

      Comment by Paul Anthony — March 18, 2008 @ 12:39 pm

    RSS feed for comments on this post.

    TrackBack URL


    Leave a Comment

     
    Quick Nav
     
    Recent News
    August 14, 2008
    Nutra Pharma Announces Initial Positive Safety Data from Clinical Study in Adrenomyeloneuropathy (AMN)


    August 6, 2008
    Nutra Pharma Announces Collaborative Agreement with Centers for Disease Control and Prevention (CDC)


    August 1, 2008
    August 2008 Shareholder Letter from Chairman and CEO Rik J. Deitsch


     
     
    Announcements
    Click Here for an Update on the Phase IIb Clinical Trial Data.
     
     
    NPC
    Privacy Policy